

ACURA PHARMACEUTICALS, INC  
Form 8-K  
September 27, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549

---

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934

September 27, 2011  
Date of Report (Date of earliest event reported)

---

ACURA PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in Charter)

---

State of New York  
(State of Other Jurisdiction  
of Incorporation)

1-10113  
(Commission File Number)

11-0853640  
(I.R.S. Employer  
Identification Number)

616 N. North Court, Suite 120  
Palatine, Illinois 60067  
(Address of principal executive offices) (Zip Code)

(847) 705-7709  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))

Item 8.01

Other Events

On September 27, 2011 we issued a press release disclosing the issuance by the U.S. Patent and Trademark Office of U.S. Patent No. 7,981,439, titled “Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof.” A copy of our press release is being furnished as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

Exhibit Number	Description
99.1	Press Release dated September 27, 2011 Announcing Issuance of U.S. Patent for Abuse Deterrent Drug Formulations.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President & Chief  
Financial Officer

Date: September 27, 2011

---

Exhibit Number	Description
99.1	Press Release dated September 27, 2011 Announcing Issuance of U.S. Patent for Abuse Deterrent Drug Formulations.

---